AURORA CANNABIS INC (ACB) Form 6-K — Sep 16, 2026
Aurora Cannabis (NASDAQ/TSX: ACB) furnished a 6-K with a September 16, 2026 business update in which the company reaffirmed its fiscal 2027 second-quarter guidance for sequential growth in quarterly net revenue and adjusted EBITDA. The update centers on the accretive acquisition of Safari Flower Company, which received EU-GMP certification in July and is expected to contribute incremental net revenue and adjusted EBITDA. Aurora also cited continued strength in Germany and Poland — where it claims the number one revenue market share — and UK expansion via the recently announced acquisitions of Internode Pharma and HAP Pharma Limited.
Key figures
- Guidance
- Reaffirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA (non-GAAP)
- Cash Position
- 149000000
- No Debt
- Yes
- Cash As Of
- June 30, 2026
- Cash Definition
- cash, restricted cash, short term investments and cash equivalents
- Poland Market Position
- #1 market share by revenue
- Safari Flower Eu Gmp Certification
- received July 2026
- Global Medical Cannabis Market Size Usd Est
- $9 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.